Cancer Chemotherapy and Pharmacology

, Volume 73, Issue 3, pp 467–473

Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies

  • Daruka Mahadevan
  • Gregory Ryan Sutton
  • Rafael Arteta-Bulos
  • Chris J. Bowden
  • Paul J. E. Miller
  • Rachel Elizabeth Swart
  • Mark S. Walker
  • Paul Haluska
  • Pamela N. Munster
  • John Marshall
  • Omid Hamid
  • Razelle Kurzrock
Original Article

Abstract

Background

R1507 is a human IgG1 Mab that binds to the insulin-like growth factor-1 receptor (IGF-1R) and inhibits IGF-1- or IGF-2-mediated anchorage-independent growth of malignant cells. A phase 1b study evaluated the safety, tolerability and efficacy of R1507 in combination with multiple standard oncology regimens.

Methods

R1507 (3, 5, 9, 10 and 16 mg/kg IV, Q2 W or Q3 W) was added to six treatment regimens: gemcitabine + erlotinib (GE); paclitaxel + bevacizumab (PB); carboplatin + etoposide (CE); mFOLFOX6 + bevacizumab (FB); capecitabine + trastuzumab (CT); and sorafenib (S). If tolerable, R1507 dose was escalated utilizing a 3 + 3 + 6 and a 3 + 9 design.

Results

A total of 104 patients enrolled into regimens 1–6: 93 % were non-recent diagnoses. Eighteen withdrew for safety [one death, 17 adverse events (AEs)]. A total of 1,337 AEs any grade, across regimens and doses were nausea, vomiting and diarrhea. A total of 123 had grade ≥3 AEs (n = 28 dose level 1; n = 95 dose level 1) and in 60 patients were myelosuppression, fatigue and mucosal inflammation. ORR (PR plus SD) of evaluable patients across six regimens was 36 % with five PRs: regimens PB (non-small cell lung cancer, nasopharyngeal cancer), CE (melanoma), FB (colon cancer) and S (GIST). The GIST pt (>4 prior therapies) had a PR for 3 years. Three patients (breast cancer, melanoma and adenoid cystic carcinoma) were on study for >1 year; 76 % of patients had SD or better for 4 months.

Conclusions

R1507 added to six standard oncology regimens was well tolerated with an ORR of 36 %.

Keywords

Solid Tumor Phase 1 IGF-R1 R1507 Oncology regimens Monoclonal antibody 

Supplementary material

280_2013_2372_MOESM1_ESM.docx (17 kb)
Supplementary material 1 (DOCX 17 kb)

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Daruka Mahadevan
    • 1
  • Gregory Ryan Sutton
    • 1
  • Rafael Arteta-Bulos
    • 1
  • Chris J. Bowden
    • 2
  • Paul J. E. Miller
    • 3
  • Rachel Elizabeth Swart
    • 4
  • Mark S. Walker
    • 3
  • Paul Haluska
    • 5
  • Pamela N. Munster
    • 6
  • John Marshall
    • 7
  • Omid Hamid
    • 8
  • Razelle Kurzrock
    • 9
  1. 1.The University of Tennessee/West ClinicMemphisUSA
  2. 2.Genentech, Inc.San FranciscoUSA
  3. 3.ACORN ResearchLLCMemphisUSA
  4. 4.Arizona Oncology/USONTucsonUSA
  5. 5.Mayo ClinicRochesterUSA
  6. 6.University of California, San FranciscoSan FranciscoUSA
  7. 7.Georgetown University HospitalWashingtonUSA
  8. 8.The Angeles Clinic and Research InstituteSanta MonicaUSA
  9. 9.University of California, San DiegoSan DiegoUSA

Personalised recommendations